Dynavax Technologies Co. (NASDAQ:DVAX) Position Lessened by Geode Capital Management LLC

Geode Capital Management LLC reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 2.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,999,935 shares of the biopharmaceutical company’s stock after selling 89,755 shares during the quarter. Geode Capital Management LLC owned about 2.28% of Dynavax Technologies worth $33,426,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its holdings in shares of Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after acquiring an additional 53,600 shares during the period. Great Point Partners LLC raised its holdings in shares of Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after buying an additional 1,109,080 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Dynavax Technologies during the second quarter worth approximately $17,615,000. Mizuho Markets Americas LLC increased its position in Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after acquiring an additional 204,475 shares during the period. Finally, Bank of Montreal Can raised its stake in Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after acquiring an additional 82,449 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $12.84 on Thursday. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.01. The firm has a market capitalization of $1.69 billion, a PE ratio of 98.78 and a beta of 1.33. The company’s 50 day simple moving average is $12.33 and its 200 day simple moving average is $11.52. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.